Navigation Links
Axel Ullrich named winner of 2009 Dr. Paul Janssen Award for Biomedical Research
Date:7/1/2009

London, 1 July, 2009 Johnson & Johnson today announced that Axel Ullrich, Ph.D., director of the Department of Molecular Biology at the Max Planck Institute of Biochemistry in Germany, whose discoveries have led to novel cancer therapies including Herceptin (trastuzumab) , is the winner of the 2009 Dr. Paul Janssen Award for Biomedical Research. An independent committee of world-renowned scientists selected Dr. Ullrich, who on September 8 will receive a $100,000 prize during a ceremony in Beerse, Belgium.

"Dr. Ullrich was chosen for his pioneering work in applying molecular biology and molecular cloning to the discovery of protein therapeutics for the treatment of a wide range of diseases, including diabetes and cancer," said Solomon Snyder, M.D., distinguished service professor of Neuroscience, Pharmacology and Psychiatry, Johns Hopkins School of Medicine and chairman of The Dr. Paul Janssen Award Selection Committee.

"He is one of few basic scientists whose work not only has influenced academic research, but also has helped millions of patients suffering from major chronic diseases," Snyder continued. "We received a number of outstanding nominations for this year's Award and are pleased to acknowledge Dr. Ullrich with this distinction. His work has had a remarkable impact on human health and truly embodies the efforts of the Award's namesake, 'Dr. Paul,' who helped save millions of lives through his contribution to the discovery and development of more than 80 medicines."

Ullrich has pioneered the translation of genomics-based discoveries into novel approaches for the treatment of major diseases. Working at Genentech, Inc. in the early 1980s, he developed genetically engineered human insulin, the first therapeutic derived from gene cloning. In 1987, Ullrich and collaborators discovered that the neu/HER2 gene is amplified and overexpressed in more than 30 percent of invasive breast cancers. HER2 was chosen for the development of an entirely novel cancer therapy, culminating in the production of an anti-HER2 monoclonal antibody that since 1998 has been used successfully to treat patients with metastatic breast cancer. This was the first targeted therapeutic agent developed on the basis of a newly discovered gene with an oncogenic function in human cancer.

In the early 1990s, Ullrich identified the signaling system involved in regulating tumor angiogenesis, the growth of blood vessels in tumors. He discovered that inhibiting a key player in the signaling system (called vascular endothelial growth factor receptor or VEGFR) suppresses the generation of blood vessels in tumors and slows down cancer cell growth. Years later, a small molecule inhibitor of the VEGFR2 kinase function was developed, from which a derivative was approved in 2006 for the treatment of kidney carcinoma and gastro-intestinal stromal tumors.

"It is an honor to receive an award of this stature and to be recognized among so many outstanding scientists," said Ullrich. "Dr. Paul is a legend whose work had a tremendous impact on combating some of the world's most serious diseases. Four of the more than 80 medicines he developed are on the World Health Organization's list of essential medicines."

"Johnson & Johnson is pleased the Selection Committee chose Dr. Ullrich as the recipient of the 2009 Dr. Paul Janssen Award, as we believe that his discoveries capture the spirit and legacy of Dr. Paul," said Paul Stoffels, M.D., global head, Research & Development, Pharmaceuticals, Johnson & Johnson. "Dr. Paul's passion for his work and dedication to creating life-saving therapies for the individuals most in need should continue to serve as an inspiration to the scientific community as we carry on with our quest to care for the world, one patient at a time."


'/>"/>

Contact: Seema Kumar Johnson & Johnson Pharmaceutical Services, L.L.C
skumar10@its.jnj.com
908-218-6460
Porter Novelli
Source:Eurekalert

Related biology news :

1. American Journal of Botany named a top 10 most influential journal of the century
2. New species of phallus-shaped mushroom named after California Academy of Sciences scientist
3. 3 prominent Cell Press journals named among the 100 most influential journals in past 100 years
4. Three prominent Cell Press journals named among the 100 most influential journals in past 100 years
5. Two Hutchinson Center researchers named HHMI Early Career Scientists
6. Peter Baumann named Howard Hughes Medical Institute Early Career Scientist
7. Whitehead member Peter Reddien named HHMI Early Career Scientist
8. Wildlife biologist named Roger Tory Peterson Medal recipient, speaker
9. Lockheed Martin Named Biometrics Company of the Year by Frost and Sullivan
10. Lockheed Martin Named Biometrics Company of the Year by Frost and Sullivan
11. UC San Diego senior named Churchill Scholar for extraordinary undergraduate research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
(Date:3/23/2017)... India , March 23, 2017 The report "Gesture ... Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, ... at a CAGR of 29.63% between 2017 and 2022. ... ... ...
Breaking Biology News(10 mins):
(Date:8/17/2017)... CA (PRWEB) , ... August 17, 2017 , ... ... for cancer research and personalized medicine, today announced the launch of a new ... City, Missouri. The study’s goal is to evaluate the potential for early detection ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... ... beneficial microbe delivery system, announced it has secured $2M in funding from an ... City Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar is ...
(Date:8/15/2017)... ... , ... Kapstone Medical is proud to announce that it has ... and inventors develop and safeguard their latest innovations. The company has grown from ... of clients in the United States and around the world. , Company Founder ...
(Date:8/15/2017)... ... August 15, 2017 , ... The Conference Forum ... 360° (IO360°) programming through a series of upcoming panels and events. The partnership culminates ... at The Roosevelt Hotel in New York City. , “With our experience in producing ...
Breaking Biology Technology: